Debt-to-equity of Spero Therapeutics, Inc. from 30 Jun 2018 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Spero Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2018 to 30 Sep 2025.
  • Spero Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 119%, a 45% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Spero Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 119% +37% +45% 30 Sep 2025
Q2 2025 116% +36% +45% 30 Jun 2025
Q1 2025 109% +31% +40% 31 Mar 2025
Q4 2024 95% +17% +21% 31 Dec 2024
Q3 2024 82% +4% +5.2% 30 Sep 2024
Q2 2024 80% +4.2% +5.6% 30 Jun 2024
Q1 2024 78% +3.7% +5% 31 Mar 2024
Q4 2023 79% -14% -15% 31 Dec 2023
Q3 2023 78% -25% -24% 30 Sep 2023
Q2 2023 76% -0.19% -0.25% 30 Jun 2023
Q1 2023 75% +10% +15% 31 Mar 2023
Q4 2022 93% +51% +124% 31 Dec 2022
Q3 2022 103% +79% +332% 30 Sep 2022
Q2 2022 76% +55% +261% 30 Jun 2022
Q1 2022 65% +44% +214% 31 Mar 2022
Q4 2021 41% +18% +80% 31 Dec 2021
Q3 2021 24% -5.6% -19% 30 Sep 2021
Q2 2021 21% -11% -34% 30 Jun 2021
Q1 2021 21% -4.9% -19% 31 Mar 2021
Q4 2020 23% +3.7% +19% 31 Dec 2020
Q3 2020 29% +16% +123% 30 Sep 2020
Q2 2020 32% +21% +206% 30 Jun 2020
Q1 2020 25% +15% +154% 31 Mar 2020
Q4 2019 19% +9.6% +99% 31 Dec 2019
Q3 2019 13% +4% +43% 30 Sep 2019
Q2 2019 10% -10% -49% 30 Jun 2019
Q1 2019 10% 31 Mar 2019
Q4 2018 9.7% 31 Dec 2018
Q3 2018 9.2% 30 Sep 2018
Q2 2018 20% 30 Jun 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.